Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shed 0.3% to $133.72. Analysts at Barclays upgraded Vertex Pharmaceuticals from equal-weight to overweight and raised the price target from $120.00 to $150.00. Share volume was 686,000, compared to an all-day average of 1.6 million
